Colgate-Palmolive's Price Target Lowered to $106 by UBS

UBS lowered its price target on Colgate-Palmolive (CL) to $106 from $109 while maintaining a Buy rating. The move reflects the firm's confidence in the company's performance and growth prospects.

UBS Group has lowered its price target for Colgate-Palmolive (NYSE:CL) to $106 from $109 while maintaining a "Buy" rating on the stock. The move reflects UBS's confidence in Colgate-Palmolive's performance and growth prospects. The new target price suggests a potential upside of 21.45% from the company's previous close [1].

Colgate-Palmolive has been the subject of various research reports in recent months. Barclays lifted its target price on the stock from $86 to $87, giving it an "equal weight" rating. Wells Fargo & Company increased its target price from $83 to $88, but assigned an "underweight" rating. JPMorgan Chase & Co. boosted its price target from $95 to $103, giving the stock an "overweight" rating. Citigroup raised its target price from $103 to $108, maintaining a "buy" rating. Piper Sandler reduced its target price from $108 to $107, assigning an "overweight" rating [1].

Colgate-Palmolive's stock has seen mixed reactions from analysts. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $101.00. Institutional investors own 80.41% of the company's stock [1].

Institutional investors have shown interest in Colgate-Palmolive. Westend Capital Management LLC increased its stake in the company by 111.1% during the first quarter. Cornerstone Planning Group LLC raised its holdings by 1,913.3%. Saudi Central Bank, Vermillion Wealth Management Inc., and Bernard Wealth Management Corp. also purchased new stakes in the company [1].

Colgate-Palmolive announced a share repurchase plan on March 20, authorizing the company to repurchase up to $5.00 billion in shares. This move suggests that management believes the stock is undervalued [1].

Colgate-Palmolive operates through two segments: Oral, Personal, and Home Care, and Pet Nutrition. The company reported $0.91 earnings per share for the quarter ending April 25, beating analyst expectations by $0.05. The company's revenue for the quarter was $4.91 billion, down 3.0% year-over-year [1].

References:
[1] https://www.marketbeat.com/instant-alerts/ubs-group-has-lowered-expectations-for-colgate-palmolive-nysecl-stock-price-2025-07-17/